Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulmimetostat in Advanced Solid Tumors and Lymphomas
NCT04104776Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Sep 2019
- Primary completion
- Feb 2030
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of tulmimetostat in solid tumor (advanced stage), diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma and 4 more (10 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Overall response rate up to 30 months and 1 more. Started Sep 2019; status: recruiting.
02
Drugs
tulmimetostat
03
Conditions
solid tumor (advanced stage)diffuse large B-cell lymphoma (DLBCL)T-cell lymphomamalignant mesotheliomacastration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04104776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04104776.